Clinical Trials Browser

Phase 1/2 × Completed × isatuximab × Clear all

NCT01084252 2024-11-01

Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies

Phase 1/2 Completed

351 enrolled 56 charts

Other hematologic neoplasm

Hematologic Neoplasms

NCT03194867 2024-06-14

Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Phase 1/2 Completed

109 enrolled 27 charts

Multiple Myeloma

NCT02812706 2024-04-01

Islands

Phase 1/2 Completed

36 enrolled 26 charts

Multiple Myeloma